Skip to content

Comparison of Magnesium Sulphate with Clonidine for Peri-op Vitals and Post-op Pain during Laparoscopic Cholecystectomy

Comparison of Intravenous Magnesium Sulphate v/s Clonidine on perioperative hemodynamic response, extubation response and postoperative pain in Laparoscopic Cholecystectomy: A Randomized Double Blind Interventional study at SMS Medical College and attached hospital during 2020-2021

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/07/035283
Enrollment
80
Registered
2021-07-30
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K819- Cholecystitis, unspecified

Interventions

Intervention1: Group A will receive Inj. Clonidine: Pre-op vitals will be recorded. Patients will be given Inj. Clonidine (2mcg/kg bolus and 1mcg/kg/hr infusion after induction of Anaesthesia and Intu

Sponsors

Sawai Mansingh Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion Criteria: ASA I & II Age group 30-60yrs Patients of both sex Patients posted for elective laparoscopic Cholecystectomy Patients who have given informed written consent

Exclusion criteria

Exclusion criteria: Exclusion Criteria: Patients with systemic disorders like uncontrolled hypertension, Diabetes mellitus, severe cardiac, hepatic, respiratory, or renal disease. Patients with history of allergy to any of the used drugs in study. Patient with any psychiatric illness or having any history of opioid intake or alcohol intake Pregnant or breast feeding mothers. Patients on Calcium channel blockers, beta blockers, alpha 2 agonists, methyl dopa, tricyclic antidepressants, benzodiazepines, monoamine oxidase inhibitors Hypermagnesaemialective laparoscopic Cholecystectomy Pregnant or breast feeding mothers. Patients on Calcium channel blockers, beta blockers, alpha 2 agonists, methyl dopa, tricyclic antidepressants, benzodiazepines, monoamine oxidase inhibitors Hypermagnesaemia

Design outcomes

Primary

MeasureTime frame
Mean Heart Rate 1.Mean Systolic Blood Pressure 2.Mean Diastolic Blood Pressure 3.Mean MAPTimepoint: These parameters would be assessed - 1.Prior to induction(baseline) 2.At end of bolus infusion(T0) 3.5 min after pneumoperitoneum(T5) 4.10mins after pneumoperitoneum(T10) 5. 15mins after pneumoperitoneum(T15) 6. 20mins after pneumoperitoneum(T20) 7. 25mins after pneumoperitoneum(T25) 8. 30mins after pneumoperitoneum(T30) 9. 35mins after pneumoperitoneum(T35) 10. 40mins after pneumoperitoneum (T40)

Secondary

MeasureTime frame
Assessment of- 1.Time to tracheal extubation, 2.Time to respond to verbal command(Awakening time), 3.Orientation time, 4.VAS Score, 5.Time to first rescue analgesia 6. No. of Rescue Analgesia in first 24hrs postoperative 7.Proportion of cases with side effectsTimepoint: VAS score will be assessed on following time periods: Immediately 30mins 1hr 3hr 6hr 12hr 24hr

Countries

India

Contacts

Public ContactDr Simran Thareja

Sawai Mansingh Medical College, Jaipur

fareedahmed10@gmail.com9414787759

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026